Journal of Antivirals & Antiretrovirals
Open Access
ISSN: 1948-5964
+44 1300 500008
ISSN: 1948-5964
+44 1300 500008
Agn�s-Laurence Chenine
Scientific Tracks Abstracts: JAA
Standardized assays to assess vaccine and antiviral drug effi cacy are key to the HIV fi eld. Th e main requirements for immunological assays (e.g., antibody neutralization and antibodydependent cellular cytotoxicity (ADCC) are the use of natural HIV target cells such as peripheral blood mononuclear cell (PBMC), and the use of HIV-1 infectious molecular clones (IMC) that i) express a reporter gene, ii) are representative of diff erent genetic clades and iii) are engineered to express heterologous envelope gene representating diff erent genetic clades. Th us far, only a clade B laboratory-adapted strain IMC was developed using these approaches; moreover, only a portion of the gp160 coding sequence is swapped. Here we described the construction of three native IMC expressing the Renilla Luciferase (LucR) gene from a Circulating Recombinant Form CRF01_AE, a clade B and a clade C; all three infect cell lines as well as primary cells. Each of these constructs was engineered to swap the full envelope gene, allowing gp160 to be expressed in its native form. Our data showed infection in TZMbl cells - one of the most common cell line used for infection neutralization assays - and a majority of them infected PBMC also. Neutralization data was also generated and diff erences where observed when compared with the commonly used pseudovirus assay. In addition, some envelopes showed diff erent neutralization profi les when expressed in homologous- vs heterologous-HIV chimeric clade. Th ese data highlight the importance of using infectious molecular clones as reagent in neutralization assay for assessing HIV-1 vaccine immunogen effi cacy.
Dr. Agn?s-Laurence Chenine obtained her Ph.D. in 2000 from Luminy University in Marseille-France where she studied HIV infection of the intestinal tract and generated CD4-independent IMC. She was a postdoctoral fellow at the Dana-Farber Cancer Institute and then an Instructor in Medicine at Harvard Medical School focusing on mucosal transmission and HIV/parasite co-infection in a non-human primate model. In 2008, she joined the Military HIV Research Program (MHRP) as a leading scientist in the department of Molecular Virology & Pathogenesis. One of her focus is to generate IMC from different HIV-1 subtypes and from acute vs chronic to complement MHRP research capability in HIV vaccine development.